Table 5.
Adjusted Endpoint Analysis of Continuous and Dichotomized (%) Outcomes
| Variablea | Escitalopram (n =64) | Placebo (n = 63) | OR (95% CI) | Adjusted P valueb |
|---|---|---|---|---|
| MSIMI, % | 35.2 32.5 to 37.8 |
17.6 15.5 to 19.7 |
2.53 (0.97 to 6.56) | .06c |
|
| ||||
| Resting WMA, n/N (%) | 27/56 (48.2) 39.0 to 57.5 |
34/56 (60.7) 51.7 to 69.8 |
1.83 (0.39 to 8.73) | .45 |
|
| ||||
| Resting ejection fraction, % |
n = 60 57.4 (55.5 to 59.3) |
n = 58 54.8 (52.9 to 56.7) |
.06 | |
|
| ||||
| Ejection fraction, mean of 3 change scores |
n = 59 −2.0 (−3.2 to −0.71) |
n = 58 −2.4 (−3.7 to −1.1) |
.65 | |
|
| ||||
| Resting SBP, mm HG |
n = 62 127.58 (124.4 to 130.8) |
n = 56 127.30 (124.0 to 130.7) |
.91 | |
|
| ||||
| SBP, mean of 3 change scores, mm HG |
n = 62 19.3 (16.7 to 22.0) |
n = 56 23.6 (20.8 to 26.4) |
.03 | |
|
| ||||
| Resting DBP, mm HG |
n = 62 70.0 (67.5 to 72.4) |
n = 56 73.1 (70.5 to 75.7) |
.09 | |
|
| ||||
| DBP, mean of 3 change scores, mm HG |
n= 62 11.4 (9.5 to 13.4) |
n = 56 12.2 (10.1 to 14.2) |
.63 | |
|
| ||||
| Resting heart rate, BPM | n = 61 65.7 (64.1 to 67.4) |
n = 56 65.8 (64.1 to 67.6) |
.94 | |
|
| ||||
| Heart rate, mean of 3 change scores, BPM |
n = 61 6.34 (5.0 to 7.7) |
n = 56 9.1 (7.8 to 10.5) |
.005 | |
|
| ||||
| BMI |
n = 60 28.0 (27.8 to 28.2) |
n = 62 28.2 (28.0 to 28.3) |
.19 | |
|
| ||||
| Weight, kg |
n = 60 84.9 (84.4 to 85.4) |
n = 62 85.4 (84.8 to 85.9) |
.20 | |
|
| ||||
| RPP, mean of 3 change scores |
n = 61 2250.8 (1933.2 to 2568.3) |
n = 56 2981.3 (2649.8 to 3312.9) |
.002 | |
|
| ||||
| VMAX, p/107 platelets/5 min |
n = 50 404.8 (304.2 to 505.4) |
n = 50 182.2 (81.6 to 282.8) |
.003 | |
|
| ||||
| KD100, nM |
n = 50 4202.4 (3328.6 to 5076.2) |
n = 50 210.1 (0.0 to 1083.9) |
<.001 | |
|
| ||||
| 5HTT, fm/mg protein |
n = 48 139.7 (126.1 to 153.4) |
n = 50 160.4 (147.0 to 173.7) |
.04 | |
|
| ||||
| Beck Depression Inventoryd | 7.4 (6.3 to 8.6) | 7.0 (5.8 to 8.2) | .60 | |
|
| ||||
| Perceived Stress Scalee | 21.4 (20.3 to 22.5) |
n = 62 21.8 (20.6 to 22.9) |
.61 | |
|
| ||||
| Hostilityf | 9.9 (9.1 to 10.7) |
n = 62 10.3 (9.5 to11.1) |
.49 | |
|
| ||||
| Hostile affectg | 1.6 (1.3 to 1.8) |
n = 62 1.8 (1.6 to 2.1) |
.12 | |
|
| ||||
| Trait anxietyh | 31.2 (29.7 to 32.6) | 32.0 (30.5 to 33.4) | .44 | |
|
| ||||
| State anxietyi | 27.9 (26.4 to 29.4) | 29.5 (28.0 to 31.1) | .15 | |
|
| ||||
| Resting negative affectj | 11.7 (8.5 to 15.0) |
n = 62 13.1 (9.8 to 16.4) |
.57 | |
|
| ||||
| Negative affect, mean of 3 change scores | 23.1 (18.5 to 27.7) |
n = 62 25.1 (20.4 to 29.7) |
.56 | |
|
| ||||
| Resting positive affectk | 80.6 (76.6 to 84.6) |
n = 62 81.0 (76.9 to 85.1) |
.89 | |
|
| ||||
| Positive affect, mean of 3 change scores | −22.6 (−27.4 to −17.9) |
n = 62 −29.41 (−34.23 to −24.60) |
.05 | |
|
| ||||
| ESIMI, % |
n = 59 45.8 (36.6 to 55.0) |
n = 61 52.5 (43.3 to 61.8) |
1.24 (0.6 to 2.58) | .56 |
|
| ||||
| Exercise capacity | ||||
| Met target, n (%) |
n =59 40 (67.8) 59.2 to 76.5 |
n = 61 50 (82.0) 74.5 to 89 |
2.57 (0.81 to 8.23) | .11 |
|
| ||||
| Duration, min |
n = 59 6.8 (6.2 to 7.3) |
n = 60 6.8 (6.2 to 7.3) |
.99 | |
|
| ||||
| Peak heart rate, BPM |
n = 59 135.5 (132.4 to 138.6) |
n = 61 138.6 (135.4 to 141.7) |
.18 | |
Except where noted, all values presented in Table 5 are adjusted endpoint scores and include 95% confidence intervals.
P values presented here are adjusted value with age, sex, and the corresponding baseline measurement.
Response rates were calculated from 10 imputed datasets: n = 225/640 for escitalopram and n = 111/630 for placebo groups, respectively.
Beck Depression Inventory: score range, 0–63 (higher score=greater severity of depressive symptoms)
Perceived stress scale: score range, 10–50 (higher score=greater levels of perceived stress)
Hostility: score range, 0–27 (higher score= greater levels of hostility)
Hostile Affect: score range, 0–5 (higher score=greater levels of hostile affect)
Trait anxiety: score range, 20–80 (higher score=greater levels of trait anxiety)
State anxiety: score range, 20–80 (higher score=greater levels of state anxiety)
Negative affect measured by visual analogue scale (0–100; higher score=greater levels of state negative affect)
Positive affect measured by visual analogue scale (0–100; higher score=greater levels of state positive affect)
Abbreviations: BMI, body mass index (weight in kg/height in cm; BPM, beats per minute; ESIMI, exercise-stress-induced myocardial ischemia; KD, platelet serotonin binding affinity; MSIMI, mental-stress-induced myocardial ischemia; MSs, mental stressors; RPP, rate-pressure product; 5HTT, platelet serotonin receptor transporter number